Ositinib, usually referred to as Ositinib Mesylate Tablets, is effective for some bone metastatic lesions and needs to be used under medical supervision. Ositinib mesylate tablets belong to the third generation of targeted EGFR mutant inhibitors and are used to treat locally advanced cancers or metastatic non-small cell lung cancers that have been tested and confirmed to be positive for the presence of EGFR mutations. Ositinib can target EGFR mutants, control the endothelial production of blood vessels between tumor tissues, and reduce the metastasis of tumor cells in the bloodstream. Therefore, it can reduce the occurrence of bone metastasis in non-small cell lung cancer. If lung cancer is accompanied by EGFR gene sensitive mutation, it belongs to the indications of drug treatment and can control bone metastasis after taking it. However, it must be used under the guidance of specialized doctors, and should not be used or stopped without authorization.